By itself, Alphabet's new Gemini model may not be a catalyst for the stock, but it is another building block for a company that is showing that it's an innovator. Meanwhile, its recent announcement ...

The company’s website has used the terms “enhanced reasoning capabilities ... notable benchmark improvements on tests such as ...

Google Gemini 2.5 advances AI intelligence with enhanced reasoning and coding—raising both possibilities and concerns.

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

Gemini 2.5 Pro is a multimodal, reasoning model that outperforms competitors from OpenAI, Anthropic, and DeepSeek on key ...